Braveheart Investment Group plc Further investment in Phasefocus Holdings Limited (8466J)
21 Agosto 2023 - 3:00AM
UK Regulatory
TIDMBRH
RNS Number : 8466J
Braveheart Investment Group plc
21 August 2023
21 August 2023
Braveheart Investment Group Plc
("Braveheart", the "Company" or the "Group")
Further investment in Phasefocus Holdings Limited
Braveheart Investment Group (AIM: BRH), is pleased to announce a
further investment into Phasefocus Holdings Limited ("Phasefocus").
The Company has purchased 18,750 new ordinary shares of one pence
each in Phasefocus at a price of GBP8 per share for a total
consideration of GBP150,000, taking Braveheart's total interest to
48.3 per cent. of the issued share capital of Phasefocus.
Phasefocus' imaging and analysis system, Livecyte(R), uses a
novel patented method for high fidelity quantitative imaging and
microscopy; this is known in the scientific literature as
'ptychography'.
As announced on 31 May 2023, Phasefocus has gained substantial
momentum during the year and its work, in particular with
distributors in Japan, China and the USA, has built a strong
pipeline of business opportunities. Phasefocus has received a
number of orders for its Livecyte(R) system, which are scheduled to
be delivered before the end of 2023.
On 14 August 2023, Phasefocus announced the launch of its
revolutionary new T-Cell Killing Assay for the Livecyte(R) cell
imaging platform
https://www.phasefocus.com/about/news-events/news/t-cell-assay-announcement
. The new assay quantifies interactions between immune cells and
cancer cells, addressing a major unmet need for researchers
developing the latest novel cancer therapies. In the assay, the
characteristics of T cell interactions in the period immediately
preceding target cell death, can be measured independently from
cytotoxicity. Livecyte's T-Cell Killing Assay offers unparalleled
insights at the single-cell level, empowering researchers to unlock
new frontiers in cancer therapy development and evaluation.
This investment by Braveheart will provide Phasefocus with the
working capital to market its new T-Cell Killing Assay and build
Livecyte(R) stock, in preparation for further anticipated orders,
and follows a GBP134,000 investment by the Company into Phasefocus
in January 2023.
In the year ended 31 December 2022, Phasefocus incurred a loss
before taxation of GBP990,854. The book value of Braveheart's
investment in Phasefocus at 31 March 2023 (prior to this
investment) was GBP2.5 million.
Trevor Brown, Chief Executive Officer of Braveheart,
commented:
"Phasefocus is making impressive progress on sales and
innovation making the decision to increase our investment an easy
one. The potential realization value of our interest also continues
to grow, reflecting these advances."
For further information:
Braveheart Investment Group plc Tel: 01738
587555
Trevor Brown, Chief Executive Officer
Viv Hallam, Executive Director
Allenby Capital Limited (Nominated Tel: 020
Adviser and Joint Broker) 3328 5656
James Reeve / George Payne
Peterhouse Capital Limited (Joint Tel: 020
Broker) 7469 0936
Duncan Vasey / Lucy Williams
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUEANPEAEKDEFA
(END) Dow Jones Newswires
August 21, 2023 02:00 ET (06:00 GMT)
Braveheart Investment (LSE:BRH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Braveheart Investment (LSE:BRH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024